Sentry Client GPO Prohibition FAQs

Friday, March 1, 2013
Sentry Client GPO Prohibition FAQs

Sentry Data Systems is closely monitoring all related guidance from governing agencies on the GPO Policy released by HRSA on February 7, 2013.

At this point in time there continues to be marketplace confusion and various interpretations of what the notification truly requires of Covered Entities (CEs).

All stakeholders are encouraged to review every release update and policy clarification provided and determine the course of action best suited to their CE.

Sentry has moved forward with the development of FAQs for our customers and is finalizing the release of our WAC feature that will provide clients the options on the addition of a WAC account.

Sentry FAQs are available at:

Sentry is committed to providing its clients with timely resources related to all updates. Please monitor the Datanex page and read all New & Noteworthy releases to review the most recent information available.

As always, 340B compliance is the responsibility of the CE.


Additional Resources:

Both OPA and Apexus have recently released clarifications and FAQs regarding the HRSA Program Notice.




Background Information:

The Health Resource and Services Administration (HRSA) and the Office of Pharmacy Affairs (OPA) released a 340B Program Notice on February 7, 2013 that provides clarification to 340B stakeholders about the Statutory Prohibition on Group Purchasing Organization Participation.

The program guidance in this policy release will affect certain hospitals participating in 340B that are required to abide by the GPO prohibition. The impacted Covered Entity (CE) types include Disproportionate Share Hospitals (DSH), Pediatric (PED) and Free Standing Cancer Centers (CAN). For the details on the full policy clarification, click on the link above.

In FAQs provided as a follow-up to the program notice, OPA has clarified that Covered Entities have 60 days (until April 7, 2013) to comply with the GPO Prohibition. CEs have this time to make certain their drug replenishment practices comply with the prohibition program notice.

About is your source for all news and events related to healthcare information technology, Sentry Data Systems and its products.


Travis Leonardi, RPh., C.P.
President, CEO
William D. Kirsh DO, MPH
Chief Medical Officer
Lidia Rodriguez-Hupp
SVP and 340B Compliance Officer
Dawn C. DeAngelo
Chief Pharmacy Officer